Manuel
Pombo Suárez
Charles University in Prague
Praga, República ChecaPublicacións en colaboración con investigadores/as de Charles University in Prague (13)
2024
-
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
The Journal of rheumatology, Vol. 51, Núm. 4, pp. 378-389
2023
-
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
Journal of Rheumatology, Vol. 50, Núm. 8, pp. 1009-1019
2022
-
After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries
Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181
-
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration
Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366
-
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
Rheumatology (Oxford, England), Vol. 61, Núm. 9, pp. 3799-3807
-
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218
-
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4741-4751
2021
-
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Annals of the Rheumatic Diseases, Vol. 80, Núm. 11, pp. 1410-1418
2020
-
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis
Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 1, pp. 17-24
-
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
RMD open, Vol. 6, Núm. 3
-
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis
Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2455-2461
2019
-
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution
Rheumatology (United Kingdom), Vol. 58, Núm. 12, pp. 2221-2229